
TNDM Stock Forecast & Price Target
TNDM Analyst Ratings
Bulls say
Tandem Diabetes Care is demonstrating a robust financial outlook, with a significant 10-11% year-over-year expected growth in US pump shipments and a noted 7% contribution from pharmacy channel revenue, which doubled sequentially. The revenue forecasts for 2026 and 2027 reflect steady increases, with a slight revision to $1.111 billion and $1.229 billion respectively, indicating ongoing strong demand and market penetration. Additionally, positive trends in new patient starts, driven by increased access to affordable pharmacy options and a growing installed base, support an optimistic trajectory for the company’s revenue growth.
Bears say
Tandem Diabetes Care has experienced significant operating losses since its inception and is projected to sustain a negative EBITDA of between -2% and -1% of revenue, indicating ongoing financial challenges. Revenue estimates for 2026 have been reduced to $1.07 billion, with US sales guidance reflecting a headwind of approximately $70 to $80 million due to Pay-Go pump shipments, alongside an anticipated decrease in new patient starts. Risks associated with increased competition, limited traction from new product launches, and the failure of the Mobi launch to generate profit could further hinder the company's ability to achieve sustainable growth and profitability.
This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.
TNDM Analyst Forecast & Price Prediction
Start investing in TNDM
Order type
Buy in
Order amount
Est. shares
0 shares